Targeted Restoration of the Intestinal Microbiota with a Simple, Defined Bacteriotherapy Resolves Relapsing Clostridium difficile Disease in Mice
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Relapsing C. difficile disease in humans is linked to a pathological imbalance within the intestinal microbiota, termed dysbiosis, which remains poorly understood. We show that mice infected with epidemic C. difficile (genotype 027/BI) develop highly contagious, chronic intestinal disease and persistent dysbiosis characterized by a distinct, simplified microbiota containing opportunistic pathogens and altered metabolite production. Chronic C. difficile 027/BI infection was refractory to vancomycin treatment leading to relapsing disease. In contrast, treatment of C. difficile 027/BI infected mice with feces from healthy mice rapidly restored a diverse, healthy microbiota and resolved C. difficile disease and contagiousness. We used this model to identify a simple mixture of six phylogenetically diverse intestinal bacteria, including novel species, which can re-establish a health-associated microbiota and clear C. difficile 027/BI infection from mice. Thus, targeting a dysbiotic microbiota with a defined mixture of phylogenetically diverse bacteria can trigger major shifts in the microbial community structure that displaces C. difficile and, as a result, resolves disease and contagiousness. Further, we demonstrate a rational approach to harness the therapeutic potential of health-associated microbial communities to treat C. difficile disease and potentially other forms of intestinal dysbiosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Whole genome (maximum likelihood) phylogeny of intestinal bacteria demonstrating the phylogenetic placement of disease-resolving bacteriotherapy bacteria (MixB) and the dominant members of the supershedder microbiota. Maximum likelihood phylogeny produced using FastTree from the concatenated protein sequence of 44 common genes (See methods). Species names marked in green indicate members of the suppressive MixB mixture, names marked in red indicate species that were commonly detected in the feces of supershedding mice, names in black are reference genomes from common intestinal bacteria that were included to provide phylogenetic context to the tree. Taxonomic designations are given at the relevant branch nodes. Adjacent pictures are transmission electron micrographs of sectioned bacterial strains that constitute MixB. Methods for sample processing and imaging have been described [33]. Scale bars are shown below bacteria.](https://figures.cochat.ai/paper-figures/d26cd52a622e48fbb6e5369ce372b754/targeted-restoration-of-the-intestinal-microbiota-with-a-simple-defined-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Decrease in Lachnospiraceae has been associated with severe CDI suggesting a protective role for members of this family51”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [51]
Experimental — accuracy not yet measuredIn the citing paper
“Bacterial strains [54, 118, 119] and metabolites [54] associated with protection from C. difficile have now been identified”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894
Velvet: Algorithms for de novo short read assembly using de Bruijn graphs
Zerbino, D. R., & Birney, E. (2008) · Genome Research · doi:10.1101/gr.074492.107 · Cited by 9,491
ARB: a software environment for sequence data
Ludwig, W. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh293 · Cited by 6,702
The Ribosomal Database Project: improved alignments and new tools for rRNA analysis
Cole, J. R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R. J., Kulam-Syed-Mohideen, A. S., McGarrell, D. M., Marsh, T., Garrity, G. M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn879 · Cited by 4,762
Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation
Letunic, I., & Bork, P. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btl529 · Cited by 3,299
Identifying bacterial genes and endosymbiont DNA with Glimmer
Delcher, A. L., Bratke, K. A., Powers, E. C., & Salzberg, S. L. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm009 · Cited by 3,134
Colonic Health: Fermentation and Short Chain Fatty Acids
Wong, J. M. W., de Souza, R., Kendall, C. W. C., Emam, A., & Jenkins, D. J. A. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200603000-00015 · Cited by 2,739
More powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715 · cited 1×
“Adjusted p-values were calculated using the Benjamini and Hochberg method [57].”
MethodSchloss, P. D., & Handelsman, J. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.3.1501-1506.2005 · Cited by 2,501
Cited by
Items 201–300 of 539
Davies, N. L., Compson, J. E., MacKenzie, B., O’Dowd, V., Oxbrow, A., Heads, J. T., Turner, A. V., Sarkar, K., Dugdale, S., Jairaj, M., et al. (2013) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00625-12 · Cited by 52
“These vancomycin controls suggested that individually housed animals had effectively been reinfected from their cage environments or had suffered a spontaneous “reactivation” of the spores remaining within their bodies, as was shown by others using a mouse model (45, 46).”
BackgroundProtective microbiomes can limit the evolution of host pathogen defense
Metcalf, C. J. E., & Koskella, B. (2019) · Evolution Letters · doi:10.1002/evl3.140 · Cited by 48
Taur, Y., & Pamer, E. G. (2014) · Nature Medicine · doi:10.1038/nm.3492 · Cited by 56
O'Loughlin, J. L., Samuelson, D. R., Braundmeier-Fleming, A. G., White, B. A., Haldorson, G. J., Stone, J. B., Lessmann, J. J., Eucker, T. P., & Konkel, M. E. (2015) · Applied and Environmental Microbiology · doi:10.1128/aem.00281-15 · Cited by 50
“For example, antibiotic treatment has been shown to promote Clostridium difficile colonization (57, 58).”
BackgroundLi, M., Wang, B., Sun, X., Tang, Y., Wei, X., Ge, B.-Y., Tang, Y., Deng, Y., He, C., Yuan, J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00824 · Cited by 58
“difficile (31) or Salmonella (32), and the results are promising.”
BackgroundThe Gut Bacterial Community Potentiates Clostridioides difficile Infection Severity
Lesniak, N. A., Schubert, A. M., Flynn, K. J., Leslie, J. L., Sinani, H., Bergin, I. L., Young, V. B., & Schloss, P. D. (2022) · mBio · doi:10.1128/mbio.01183-22 · Cited by 53
“difficile strains or 241 ribotypes in mice with similar microbiota as a proxy for variation in disease, such as strain 242 630 for non-severe and RT027 for severe (19, 28, 29, 48).”
BackgroundTvede, M., Tinggaard, M., & Helms, M. (2014) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.07.003 · Cited by 54
“It has also been shown that a mixture of six intestinal bacterial strains resolved CDI in mice [18].”
BackgroundKlemm, E. J., & Dougan, G. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.04.015 · Cited by 62
“For example, isolates of lineage 027/B1 are more pathogenic for the mouse than other lineages, such as 017, and furthermore, 027 isolates are highly transmissible in comparison to many other lineages (Lawley et al., 2012).”
BackgroundSteering ecological-evolutionary dynamics to improve artificial selection of microbial communities
Xie, L., & Shou, W. (2021) · Nature Communications · doi:10.1038/s41467-021-26647-4 · Cited by 59
Understanding and Modulating Mammalian-Microbial Communication for Improved Human Health
Mani, S., Boelsterli, U. A., & Redinbo, M. R. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140007 · Cited by 48
“In recent years, an example of the successful intestinal targeting of microbiota for the purposes of therapy involved fecal replacement (displacement) of Clostridium difficile infection using fecal admixtures from uninfected individuals and rodents (74, 75).”
BackgroundWu, Z., Xu, Q., Gu, S., Chen, Y., Lv, L., Zheng, B., Wang, Q., Wang, K., Wang, S., Xia, J., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.841920 · Cited by 57
Pizarro‐Guajardo, M., Calderón-Romero, P., & Paredes‐Sabja, D. (2016) · Applied and Environmental Microbiology · doi:10.1128/aem.01463-16 · Cited by 47
“zation resistance barrier against enteric pathogens (4, 5), and (ii)”
BackgroundTherapeutic manipulation of the microbiota: past, present, and considerations for the future
Young, V. B. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.09.001 · Cited by 54
Khoruts, A., & Weingarden, A. R. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.07.016 · Cited by 47
“An average patient with RCDI in our clinical practice has had >5 antibiotic courses for the infection [30], and prolonged tapered or pulsed courses of vancomycin or similarly long sequential treatments with several antibiotics, e.g., vancomycin and rifaximin, constitute standard practice approaches in RCDI.”
BackgroundInfluentialThe Challenge and Potential of Metagenomics in the Clinic
Mulcahy, H., & Workentine, M. L. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00029 · Cited by 58
BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection
Solbach, P., Chhatwal, P., Woltemate, S., Tacconelli, E., Buhl, M., Gerhard, M., Thoeringer, C. K., Vehreschild, M. J. G. T., Jazmati, N., Rupp, J., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0196977 · Cited by 46
Segal, J. P., Mullish, B. H., Quraishi, M. N., Iqbal, T. H., Marchesi, J. R., & Sokol, H. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820946904 · Cited by 51
Ferreyra, J. A., Ng, K. M., & Sonnenburg, J. L. (2014) · Cellular Microbiology · doi:10.1111/cmi.12300 · Cited by 45
“Notably, several other six species cocktails were ineffective, and colonizations with individual species from the ‘magic’ combination of six species were not able to outcompete C. difficile (Lawley et al., 2012).”
Background(2014) · PubMed Central · Cited by 45
Gal, A., Barko, P. C., Biggs, P. J., Gedye, K. R., Midwinter, A. C., Williams, D. A., Burchell, R. K., & Pazzi, P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250344 · Cited by 55
“In that context, previous studies demonstrated significant decreases in the fecal microbial diversity in a mouse model of RCI and in human patients with RCI [14–17, 50] that increase following fecal microbial transplantation [15, 16, 50, 51] and is temporally associated with resolution of the disease [15, 20, 52].”
ResultCrobach, M. J. T., Ducarmon, Q. R., Terveer, E. M., Harmanus, C., Sanders, I. M. J. G., Verduin, K., Kuijper, E. J., & Zwittink, R. D. (2020) · Microorganisms · doi:10.3390/microorganisms8050677 · Cited by 46
Replenishing our defensive microbes
Ursell, L. K., Treuren, W. V., Metcalf, J. L., Pirrung, M., Gewirtz, A., & Knight, R. (2013) · BioEssays · doi:10.1002/bies.201300018 · Cited by 43
“protection; in others, such as [5, 6], half a dozen specific members are required; and yet others, such as [7, 8], require the action of a much larger community in aggregate.”
BackgroundAdministration of defined microbiota is protective in a murine Salmonella infection model
Martz, S.-L. E., McDonald, J. A. K., Sun, J., Zhang, Y.-G., Gloor, G. B., Noordhof, C., He, S.-M., Gerbaba, T. K., Blennerhassett, M., Hurlbut, D. J., et al. (2015) · Scientific Reports · doi:10.1038/srep16094 · Cited by 43
The human microbiome and juvenile idiopathic arthritis
Verwoerd, A., ter Haar, N. M., de Roock, S., Vastert, S. J., & Bogaert, D. (2016) · Pediatric Rheumatology · doi:10.1186/s12969-016-0114-4 · Cited by 52
“Interestingly, initiatives are now being taken to culture targeted combinations of bacteria in vitro that can restore intestinal homeostasis [68, 69].”
BackgroundUpdates on Clostridium difficile spore biology
Gil, F., Lagos-Moraga, S., Calderón-Romero, P., Pizarro‐Guajardo, M., & Paredes‐Sabja, D. (2017) · Anaerobe · doi:10.1016/j.anaerobe.2017.02.018 · Cited by 58
Microbiota-Based Therapies for Clostridium difficile and Antibiotic-Resistant Enteric Infections
Lewis, B. B., & Pamer, E. G. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090816-093549 · Cited by 51
Clostridium difficile Infection
Gerding, D. N., & Young, V. B. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00245-9 · Cited by 45
The emerging metabolic view of Clostridium difficile pathogenesis
Hryckowian, A. J., Pruss, K. M., & Sonnenburg, J. L. (2016) · Current Opinion in Microbiology · doi:10.1016/j.mib.2016.11.006 · Cited by 47
Liu, C., Tang, X., Yu, J., Zhang, H., & Li, X. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.08.037 · Cited by 45
Probiotic Product Enhances Susceptibility of Mice to Cryptosporidiosis
Oliveira, B. C. M., & Widmer, G. (2018) · Applied and Environmental Microbiology · doi:10.1128/aem.01408-18 · Cited by 61
“at testing the benefits of fecal transplants (13) and defined probiotics (14–16).”
BackgroundStecher, B. (2021) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2021.151484 · Cited by 50
Jung, J. H., Kim, S. E., Suk, K. T., & Kim, D. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.913842 · Cited by 48
“In each study, dysbiosis has been used to define a change in the composition of the gut microbiota, disturbance and loss of diversity (27), or a condition that negatively affects the host through an imbalance in the gut microbiota (28).”
MethodThe Evolving Landscape of Fecal Microbial Transplantation
Shao, T., Hsu, R., Hacein-Bey, C., Zhang, W., Gao, L., Kurth, M. J., Zhao, H., Shuai, Z., & Leung, P. S. C. (2023) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-023-08958-0 · Cited by 48
“On the other hand, FMT after vancomycin treatment can clear C. difficile and lead to a diverse, healthy microbiota, indicating FMT provides additional assistance in the restoration of the gut microbiota [38, 39].”
Leslie, J. L., Vendrov, K. C., Jenior, M. L., & Young, V. B. (2019) · mSphere · doi:10.1128/mspheredirect.00698-18 · Cited by 54
The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection
Faghihkhorasani, A., Ahmed, H. H., Mashool, N. M., Alwan, M., Assefi, M., Adab, A. H., Yasamineh, S., Gholizadeh, O., & Baghani, M. (2023) · Virology Journal · doi:10.1186/s12985-023-02183-z · Cited by 47
“Producing and delivering the active compound(s) in vivo through a synthetic chassis reduces treatment costs by eliminating the requirement for purification and formulation [34].”
BackgroundThe intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis
Costello, M., Robinson, P. C., Benham, H., & Brown, M. A. (2015) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2015.08.001 · Cited by 51
The microbiota and immune response during Clostridium difficile infection
Buonomo, E. L., & Petri, W. A. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.05.009 · Cited by 55
“The transfer of six phylogenetically diverse intestinal bacteria was sufficient to clear CDI in mice [33].”
Cairns, J., Jokela, R., Becks, L., Mustonen, V., & Hiltunen, T. (2020) · Nature Ecology & Evolution · doi:10.1038/s41559-020-1272-9 · Cited by 47
Siepert, B., Reinhardt, N., Kreuzer-Redmer, S., Bondzio, A., Twardziok, S. O., Brockmann, G. A., Nöckler, K., Szabó, I., Janczyk, P., Pieper, R., et al. (2013) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2013.10.013 · Cited by 46
The potential for emerging therapeutic options forClostridium difficileinfection
Mathur, H., Rea, M. C., Cotter, P. D., Ross, R. P., & Hill, C. (2014) · Gut Microbes · doi:10.4161/19490976.2014.983768 · Cited by 43
“difficile R027-infected mice, in a recent in vivo trial.(114) During CDI resolution, 4 out of the 6 bacterial strains managed to colonize the mice while several other commensals also proliferated, increasing the microbial diversity in doing so.”
BackgroundThe Rhoptry Pseudokinase ROP54 Modulates Toxoplasma gondii Virulence and Host GBP2 Loading
Kim, E. W., Nadipuram, S. M., Tetlow, A. L., Barshop, W. D., Liu, P. T., Wohlschlegel, J. A., & Bradley, P. J. (2016) · mSphere · doi:10.1128/msphere.00045-16 · Cited by 42
Spinler, J. K., Ross, C. L., & Savidge, T. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.05.007 · Cited by 46
Microbiota and pathogen ‘pas de deux’: setting up and breaking down barriers to intestinal infection
McKenney, E. S., & Kendall, M. M. (2016) · Pathogens and Disease · doi:10.1093/femspd/ftw051 · Cited by 44
“In general, succinate does not accumulate to significant levels in the gut; however, succinate levels increase during intestinal inflammation, such as during antibiotic-associated diarrhea and during CDI in humans and mice (Lawley et al. 2012).”
BackgroundHart, S. F. M., Mi, H., Green, R., Xie, L., Pineda, J. M. B., Momeni, B., & Shou, W. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000135 · Cited by 42
Pathogenesis of Clostridium difficile Infection and Its Potential Role in Inflammatory Bowel Disease
Monaghan, T. M., Cockayne, A., & Mahida, Y. R. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000461 · Cited by 38
“difficile.(135) Administration of a mixture of 10 different facultatively aerobic”
BackgroundBacteriotherapy for the treatment of intestinal dysbiosis caused by Clostridium difficile infection
Adamu, B. O., & Lawley, T. D. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.06.009 · Cited by 48
“com the microbiota diversity during disease resolution [48].”
BackgroundLee, W. J., Lattimer, L., Stephen, S., Borum, M. L., & Doman, D. B. (2015) · PubMed Central · Cited by 44
Taguer, M., & Maurice, C. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.366 · Cited by 37
“To circumvent this, several teams are currently looking into identifying a cohort of selected bacterial taxa that will confer an adequate level of colonization resistance while also ensuring key ecosystem functions.(80) However, how to ensure the stability and”
BackgroundThiemann, S., Smit, N., & Strowig, T. (2016) · Current topics in microbiology and immunology · doi:10.1007/82_2016_504 · Cited by 47
“This is supported by studies, which showed that species of a mixture of donor bacteria are lost over time or do not fully colonize (Lawley et al. 2012; Petrof et al. 2013), alteration through addition of microbes increase the S.”
MethodAabed, K., Bhat, R. S., Moubayed, N., Al-Mutiri, M., Al-Marshoud, M., Alqahtani, A. M., & El-Ansary, A. (2019) · Cellular and Molecular Biology · doi:10.14715/cmb/2019.65.1.1 · Cited by 44
“2 and transplanting it anorectally into the study group daily for 5 days (16).”
BackgroundFrisbee, A. L., & Petri, W. A. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.01.009 · Cited by 46
“difficile 027/BI and promote recovery from antibiotic associated dysbiosis[22].”
Greathouse, K. L., Harris, C. C., & Bultman, S. J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2014.12.016 · Cited by 39
“…in the resistance against germination of C. difficile spores, others have shown that members of the Bacteroides and Ruminococcaceae families are associated with CDI resistance in humans, of which Lachnospiracea and Ruminococcaceae are butyrate producers (Lawley et al., 2012; Schubert et al., 2014).”
BackgroundZhang, K., Zhang, Q., Qiu, H., Ma, Y., Hou, N., Zhang, J., Kan, C., Han, F., Sun, X., & Shi, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37609 · Cited by 48
Lin, C., Wan, J., Su, Y., & Zhu, W. (2018) · Metabolites · doi:10.3390/metabo8040089 · Cited by 44
“FMT was proven to increase the reshaping of mouse intestinal microbiota [15,16], but this has rarely been investigated in neonatal piglets.”
BackgroundSociability in a non-captive macaque population is associated with beneficial gut bacteria
Johnson, K. V. ‐., Watson, K. K., Dunbar, R., & Burnet, P. W. J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1032495 · Cited by 36
“The role of social behaviour in influencing microbiome composition may therefore have implications for host health and fitness, since transmission of beneficial microorganisms and a more diverse microbiome may help to protect hosts from pathogens (Dillon et al., 2005; Koch and Schmid-Hempel, 2011; Lawley et al., 2012;…”
BackgroundImmunological consequences of microbiome-based therapeutics
Alam, M. Z., Maslanka, J. R., & Abt, M. C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1046472 · Cited by 43
Recurrent Clostridium difficile infection and the microbiome
Almeida, R., Gerbaba, T. K., & Petrof, E. O. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1099-3 · Cited by 38
“simple mixture of six phylogenetically diverse bacteria that triggered the expansion of health-associated bacteria when administered as a mixture rather than as individual species, suggesting that both species composition and diversity are important factors in the design of bacteriotherapy [98].”
Etienne‐Mesmin, L., Chassaing, B., Adekunle, O., Mattei, L. M., Bushman, F. D., & Gewirtz, A. T. (2017) · Gut · doi:10.1136/gutjnl-2016-313510 · Cited by 36
“difficile can be present but yet undetectable by culture was demonstrated by Lawley and colleagues, whom observed that, even in stringently hygienic conditions, mice that had seemingly fully resolved a CDI would bloom the bacteria upon antibiotherapy [25].”
BackgroundByproduct Cross Feeding and Community Stability in an In Silico Biofilm Model of the Gut Microbiome
Henson, M. A., & Phalak, P. (2017) · Processes · doi:10.3390/pr5010013 · Cited by 40
“For example, Clostridium difficile infections are often attributed to the use of broad spectrum antibiotics that inadvertently alter microbiota diversity and species composition, thereby reducing colonization resistance to pathogen invasion [44,45].”
BackgroundLi, X., Kang, Y., Huang, Y., Xiao, Y., Song, L., Lu, S., & Ren, Z. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111290 · Cited by 39
Advances in the Microbiome: Applications to Clostridium difficile Infection
Culligan, E. P., & Sleator, R. D. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5090083 · Cited by 39
“A similar study has previously been shown to be successful for the prevention of recurrent CDI in mice, where the authors used a defined, six-species cocktail of bacteria including Staphylococcus warneri, Enterococcus hirae, Lactobacillus reuteri, and novel species from the genera Anaerostipes, Bacteroides and Enteror…”
BackgroundFrom complex gut communities to minimal microbiomes via cultivation
Clavel, T., Lagkouvardos, I., & Stecher, B. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.05.013 · Cited by 39
Kassam, Z., Lee, C., & Hunt, R. H. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.08.007 · Cited by 34
Novel antibiotics in development to treat Clostridium difficile infection
Bassères, E., Endres, B. T., Dotson, K. M., Alam, M. J., & Garey, K. W. (2016) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000332 · Cited by 32
Howerton, A., Seymour, C. O., Murugapiran, S. K., Liao, Z., Phan, J. R., Estrada, A., Wagner, A. J., Mefferd, C. C., Hedlund, B. P., & Abel‐Santos, E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02251-17 · Cited by 30
Bacterial Gut Microbiota and Infections During Early Childhood
George, S., Aguilera, X., Gallardo, P., Farfán, M. J., Lucero, Y., Torres, J. P., Vidal, R. M., & O’Ryan, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.793050 · Cited by 36
Murine models to study Clostridium difficile infection and transmission
Lawley, T. D., & Young, V. B. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.09.008 · Cited by 31
“difficile disease in mice as effectively as whole-fecal transplants [21].”
BackgroundInfluentialAn ensemble approach to the structure-function problem in microbial communities
Gopalakrishnappa, C., Gowda, K., Prabhakara, K., & Kuehn, S. (2022) · iScience · doi:10.1016/j.isci.2022.103761 · Cited by 35
“There exists tantalizing evidence that this can be done, for example, by altering metabolic phenotypes (Turnbaugh et al., 2006) or treating persistent infections (Lawley et al., 2012), but we lack general approaches for developing such strategies.”
BackgroundLeber, A. J., Viladomiu, M., Hontecillas, R., Abedi, V., Philipson, C. W., Hoops, S., Howard, B. A., & Bassaganya-Riera, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134849 · Cited by 34
“Currently, numerous methods of alleviation of these treatment methods are under investigation, including the development of vaccines, toxin-based antibodies and microbiome reconstitution [7, 29, 30].”
BackgroundMethodKoenigsknecht, M. J., & Young, V. B. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328365d326 · Cited by 36
Li, Y., Xu, S., Xu, Q., & Chen, Y. (2020) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1709856 · Cited by 30
“difficile infection exhibited significant signs of chronic intestinal disease and also markedly increased proinflammatory factor expression in caecal tissue of mice, similar to the human immune response [40,41].”
BackgroundRetractedNigam, M., Panwar, A. S., & SINGH, R. K. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2022.961569 · Cited by 38
The rest of the story: the microbiome and gastrointestinal infections
Leslie, J. L., & Young, V. B. (2014) · Current Opinion in Microbiology · doi:10.1016/j.mib.2014.11.010 · Cited by 33
Spencer, J., Leuzzi, R., Buckley, A. M., Irvine, J. J., Candlish, D., Scarselli, M., & Douce, G. R. (2014) · Gut Microbes · doi:10.4161/gmic.27712 · Cited by 38
Fecal Microbiota Transplant Protocol forClostridium DifficileInfection
Tauxe, W. M., Dhere, T., Ward, A., Racsa, L. D., Varkey, J. B., & Kraft, C. S. (2015) · Laboratory Medicine · doi:10.1309/lmci95m0twpdzkod · Cited by 29
Bi, X.-D., Lu, B.-Z., Pan, X.-X., Liu, S., & Wang, J. (2021) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-021-00544-3 · Cited by 29
“It has been postulated that a collection of functionally distinct bacterial species rationally selected from the human gut microbiome may be more effective than single strains in preventing/treating disease [35], supporting our hypothesis that the combination sixproduct strain used here may be more effective than any…”
BackgroundGut Microbiota Metabolites Mediate Bax to Reduce Neuronal Apoptosis via cGAS/STING Axis in Epilepsy
Zhai, J., Wang, C., Liang, J., Liu, F., Xiao, Y., Gu, H., Liu, M.-J., & Chen, Y. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03545-y · Cited by 30
“The dosing of antibiotics was based on previous studies that used ampicillin [17–19], neomycin and bacitracin [20], vancomycin[21], and meropenem [22, 23].”
Horvat, S., & Rupnik, M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01633 · Cited by 32
How the Anaerobic Enteropathogen Clostridioides difficile Tolerates Low O 2 Tensions
Kint, N., Feliciano, C. A., Martins, M. C., Morvan, C., Fernandes, S. F., Folgosa, F., Dupuy, B., Texeira, M., & Martin‐Verstraete, I. (2020) · mBio · doi:10.1128/mbio.01559-20 · Cited by 45
“C. difficile strains were grown anaerobically (5% H2, 5% CO2, 90% N2) in TY (Bacto tryptone, 30 g liter 1, yeast extract, 20 g liter 1 [pH 7.4]), in Pep-M (71), or in C. difficile minimal medium (CDMM) (72).”
BackgroundInfluentialFecal microbiota transplantation for Clostridium difficile infection: benefits and barriers
Lo Vecchio, A., & Cohen, M. B. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000023 · Cited by 27
Horowitz, R. I., & Freeman, P. R. (2019) · International Journal of General Medicine · doi:10.2147/ijgm.s193608 · Cited by 32
Gosens, R., Hiemstra, P. S., Adcock, I. M., Bracke, K. R., Dickson, R. P., Hansbro, P. M., Krauss‐Etschmann, S., Smits, H. H., Stassen, F. R. M., & Bartel, S. (2020) · European Respiratory Journal · doi:10.1183/13993003.02320-2019 · Cited by 31
A human gut ecosystem protects against C. difficile disease by targeting TcdA
Martz, S., Guzmán-Rodríguez, M., He, S.-M., Noordhof, C., Hurlbut, D. J., Gloor, G. B., Carlucci, C., Weese, J. S., Allen‐Vercoe, E., Sun, J., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1232-y · Cited by 29
“Although not entirely understood, proposed mechanisms of action for FMT include modulation of host immune function [8], effects on bile salt Electronic supplementary material The online version of this article (doi:10.1007/s00535-016-1232-y) contains supplementary material, which is available to authorized users.”
InfluentialDiagnosis and Management of Clostridium difficile Infection
Korman, T. M. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1398741 · Cited by 34
Kubota, H., Makino, H., Gawad, A., Kushiro, A., Ishikawa, E., Sakai, T., Akiyama, T., Matsuda, K., Martín, R., Knol, J., et al. (2016) · Applied and Environmental Microbiology · doi:10.1128/aem.01540-16 · Cited by 26
Lesniak, N. A., Schubert, A. M., Sinani, H., & Schloss, P. D. (2021) · mSphere · doi:10.1128/msphere.01238-20 · Cited by 28
“difficile colonization resistance in 235 either a set of closely related murine communities or collectively across many different susceptible 236 communities (11, 15, 22).”
BackgroundInfluentialSteering and controlling evolution — from bioengineering to fighting pathogens
Lässig, M., Mustonen, V., & Nourmohammad, A. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00623-8 · Cited by 32
“3) or the reduction of diversity in a microbial community 149 .”
BackgroundFecal Microbiota Transplantation: Information for the Pediatrician
Oliva‐Hemker, M. M., Kahn, S. A., Steinbach, W. J., SECTION ON GASTROENTEROLOY, H., Cohen, M. B., Brumbaugh, D. E., Cole, C. R., Dotson, J. L., Harpavat, S., Lightdale, J. R., et al. (2023) · PEDIATRICS · doi:10.1542/peds.2023-062922 · Cited by 30
Consortium of Probiotics Attenuates Colonization of Clostridioides difficile
Li, X., Chu, Q., Huang, Y., Xiao, Y., Song, L., Zhu, S., Kang, Y., Lu, S., Xu, J., & Ren, Z. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02871 · Cited by 30
Fecal Microbiota Transplantation for Clostridium difficile Infection: The Ochsner Experience.
Ray, A., Smith, R., & Breaux, J. (2014) · PubMed Central · Cited by 26
Tomkovich, S., Stough, J. M. A., Bishop, L., & Schloss, P. D. (2020) · mSphere · doi:10.1128/msphere.00869-20 · Cited by 23
“Sex has been shown to influence microbiota variation in mice (44), so we used female mice to reduce this confounding variable and also to match the sex used in previous CDI studies that administered clindamycin to mice (31, 32, 43, 45).”
BackgroundMethodTomkovich, S., Taylor, A., King, J., Colovas, J., Bishop, L., McBride, K., Royzenblat, S. K., Lesniak, N. A., Bergin, I. L., & Schloss, P. D. (2021) · mSphere · doi:10.1128/msphere.00629-21 · Cited by 24
The human microbiota associated with overall health
Xu, X., Wang, Z., & Zhang, X. (2013) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.819485 · Cited by 29
“Recently, Lawley et al. (2012) showed that the treatment of C. difficile 027/BI infected mice with feces from healthy mice rapidly restored a diverse and healthy microbiota, and resolved C. difficile disease and contagiousness.”
BackgroundNovel avenues forClostridium difficileinfection drug discovery
Zucca, M., Scutera, S., & Savoia, D. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.770466 · Cited by 28
“, in the resolution of intestinal disease and contagiousness [149].”
BackgroundMoving Fecal Microbiota Transplantation Into the Mainstream
Orenstein, R., Griesbach, C. L., & DiBaise, J. K. (2013) · Nutrition in Clinical Practice · doi:10.1177/0884533613497516 · Cited by 27
Bile Salt Inhibition of Host Cell Damage by Clostridium Difficile Toxins
Darkoh, C., Brown, E. L., Kaplan, H. B., & DuPont, H. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079631 · Cited by 27
“The foundation of CDI is the ability of this multiple antibioticresistant bacterium to overpopulate the human gastrointestinal tract following reduction of the normal gut microbiota by antibiotic therapy [33,34].”
BackgroundInfluentialHarnessing Microbiota to Kill a Pathogen: The sweet tooth of Clostridium difficile
Ley, R. E. (2014) · Nature Medicine · doi:10.1038/nm.3494 · Cited by 27
Park, L., Mone, A., Price, J. C., Tzimas, D., Hirsh, J., Poles, M. A., Malter, L., & Chen, L. A. (2016) · Annals of Gastroenterology · doi:10.20524/aog.2016.0098 · Cited by 28
“Other studies in mice and humans have shown that treatment with a limited number of gut bacteria can also cure CDAD, suggesting that transplantation of certain microbial functions, rather than merely diversity, is important [20-22].”
BackgroundEngineering microbes for targeted strikes against human pathogens
Hwang, I. Y., Lee, H. L., Huang, J. G., Lim, Y. Y., Yew, W. S., Lee, Y. S., & Chang, M. W. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2827-7 · Cited by 25
Longitudinal microbiome profiling reveals impermanence of probiotic bacteria in domestic pigeons
Grond, K., Perreau, J. M., Loo, W. T., Spring, A. J., Cavanaugh, C. M., & Hird, S. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217804 · Cited by 24
Metadata
- Authors
- Lawley, T. D., Clare, S., Walker, A. W., Stares, M. D., Connor, T. R., Raisen, C., Goulding, D., Rad, R., Schreiber, F., Brandt, C., Deakin, L. J., Pickard, D. J., Duncan, S. H., Flint, H. J., Clark, T. G., Parkhill, J., & Dougan, G.
- Affiliations
- Wellcome Sanger Institute (GB)
- University of Aberdeen (GB)
- London School of Hygiene & Tropical Medicine (GB)
- Corresponding author
- Lawley, Trevor D.
- ORCID
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-25
- Volume
- 8
- Issue
- 10
- Pages
- e1002995
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC3486913
- OpenAlex
- W2171605634
- Cited by
- 540
- References
- 73
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 19 · 2023: 20 · 2022: 24 · 2021: 33 · 2020: 21 · 2019: 37 · 2018: 47 · 2017: 42 · 2016: 71 · 2015: 65 · 2014: 73 · 2013: 61 · 2012: 6
- FWCI
- 45.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Wellcome Trust (076964, 098051)
- Medical Research Council (098051, 93614)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Clostridium difficile infection, gut microbiota, dysbiosis, bacterial therapy, fecal microbiota transplantation, transmissibility, opportunistic pathogens, microbial metabolites, mouse model
- MeSH terms
- Animals, Enterocolitis, Pseudomembranous, Feces, Female, Intestines, Mice, Inbred C3H, Mice, Inbred C57BL, Molecular Sequence Data, Recurrence, Vancomycin, Clostridioides difficile, Probiotics, Drug Resistance, Bacterial, Mice, Microbial Interactions, Microbial Consortia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.